<DOC>
	<DOCNO>NCT01926548</DOCNO>
	<brief_summary>This study design evaluate pharmacokinetics CJ Imatinib mesylate tablet 1 x 200mg compare Gleevec film-coated tablet 2 x 100mg healthy male volunteer .</brief_summary>
	<brief_title>Evaluate Pharmacokinetics ( Cmax , Auc ) CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Male volunteer age 20 55 year old Judged good health basis vital sign , ECG , physical exam routine laboratory data Body Mass Index ( BMI ) range 18.5 27 kg/m2 Available entire study period Willing adhere protocol requirement sign inform consent form History clinically significant hepatic , renal , neurology , psychiatric , pulmonary , endocrine , hematologic , cardiovascular disease Clinically significant vital sign SBP ( Systolic Blood Pressure ) ≤ 90 mmHg SBP ≥ 140 mmHg DBP ( Diastolic Blood Pressure ) ≤ 60 mmHg DBP ≥ 100 mmHg History surgery except gastrointestinal disease might significantly change absorption medicine History clinically significant allergy , include imatinib Clinical laboratory test value outside accept normal range AST ( ASpartate Transaminase ) , ALT ( ALanine Transaminase ) ( &gt; 1.5 time normal range Estimated GFR ( Glomerular Filtration Rate ) &lt; 80 mL/min History caffeine , alcohol , smoke abuse caffeine &gt; 4 cups/day grapefruit juice &gt; 4 cups/day smoking &gt; 20 cigarettes/day alcohol &gt; 140g/week Participated previous clinical trial within 3 month prior dose Donated blood within 60 day prior dose Use prescription medicine oriental medicine within 14 day dose use nonprescription medicine within 10 day dose Subjects consider unsuitable base medical judgement investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>